专利检索 ap:("Boehringer Ingelheim International GmbH") AND inv:"ZIMDAHL-GELLING, Heike" 第 1 页

1.

发明授权
TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN 有权

公开(公告)号：EP2504002B1

公开(公告)日：2019-10-09

申请号：EP10785054.7

申请日：2010-11-26

申请人： Boehringer Ingelheim International GmbH

发明人： DUGI, Klaus , GRAEFE-MODY, Eva, Ulrike , MARK, Michael , WOERLE, Hans-Juergen , ZIMDAHL-GELLING, Heike

IPC分类号： A61K31/155 , A61K31/44 , A61K31/519 , A61K45/06 , A61P3/10

2.

发明公开
TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN 审中-公开

公开(公告)号：EP3646859A1

公开(公告)日：2020-05-06

申请号：EP19202034.5

申请日：2010-11-26

申请人： Boehringer Ingelheim International GmbH

发明人： DUGI, Klaus , GRAEFE-MODY, Eva Ulrike , MARK, Michael , WOERLE, Hans-Juergen , ZIMDAHL-GELLING, Heike

IPC分类号： A61K31/155 , A61K31/44 , A61K31/519 , A61K45/06 , A61P3/10

摘要： The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

3.

发明公开
TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN 审中-公开
标题翻译： BEHANDLUNG VON基因治疗糖尿病 - 麻醉药DPP-IV-HEMMERN WIE ETWA LINAGLIPTIN

公开(公告)号：EP2504002A1

公开(公告)日：2012-10-03

申请号：EP10785054.7

申请日：2010-11-26

申请人： Boehringer Ingelheim International GmbH

发明人： DUGI, Klaus , GRAEFE-MODY, Eva, Ulrike , MARK, Michael , WOERLE, Hans-Juergen , ZIMDAHL-GELLING, Heike

IPC分类号： A61K31/155 , A61K31/44 , A61K31/519 , A61K45/06

摘要： The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.

摘要翻译： 本发明涉及用于预防或治疗代谢紊乱和相关病症的方法，例如在某些患者组中。